Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:22:53 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:JAGX - JAGUAR HEALTH INC - https://jaguar.health
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JAGX - Q12.80.2145·0.21810.20.215+0.03519.451,117.19,52612,6530.1914  0.2188  0.18251.22  0.051213:03:0108:3215 min RT 2¢

Recent Trades - Last 10 of 12653
Time ETExPriceChangeVolume
13:03:06Q0.21530.0353100
13:03:06Q0.21530.0353100
13:03:06Q0.21530.0353100
13:03:06Q0.21530.0353100
13:03:06Q0.21530.0353300
13:03:06Q0.21530.0353300
13:03:06Q0.21530.03531,500
13:03:06Q0.21530.0353212
13:03:06Q0.21530.0353336
13:03:06Q0.21530.0353900

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-29 08:32U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
2024-04-22 10:01U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
2024-04-18 08:42U:JAGXNews ReleaseJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
2024-04-16 08:33U:JAGXNews ReleaseJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
2024-04-09 16:17U:JAGXNews ReleaseJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
2024-04-08 08:32U:JAGXNews ReleaseJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
2024-04-02 08:55U:JAGXNews ReleaseJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
2024-04-01 08:03U:JAGXNews ReleaseJaguar Health Reports 2023 Financial Results
2024-03-27 08:32U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
2024-03-20 08:32U:JAGXNews ReleaseGEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
2024-02-23 08:33U:JAGXNews ReleaseJaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
2024-02-15 08:33U:JAGXNews ReleaseJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2024-02-14 08:32U:JAGXNews ReleaseJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
2024-02-12 08:33U:JAGXNews ReleaseJaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
2024-01-30 08:48U:JAGXNews ReleaseMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
2024-01-29 08:32U:JAGXNews ReleaseJaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
2024-01-25 08:34U:JAGXNews ReleaseDog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health ¢ € ™s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
2024-01-05 16:16U:JAGXNews ReleaseJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 08:31U:JAGXNews ReleaseIssuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)